Menu
MainGroup of companiesHistory2013 - 2009

2013 - 2009

Increased attention from the state authorities to the development and strengthening of the pharmaceutical industry in the country becomes a cornerstone for the company’s long-term strategic plan. As one of the leading Russian pharmaceutical manufacturers and market experts, GEROPHARM entered into an open dialogue with the authorities. It was the era of industrialization for the company: major projects were implemented on creation of modern pharmaceutical infrastructure in regional clusters: research and development center, GMP-compliant production facilities. GEROPHARM was transformed into a group of companies, where the development of drugs and biotechnology production became important areas of corporate strategy.

2013:

  • The team of the group of companies included more than 600 employees
  • At the end of 2012, the company turnover exceeded 2 billion RUB
  • The company initiated Photo Project “Diabetes in Persons”, which was first presented at the opening of the plant of GEROPHARM-Bio
  • Milestone event of the year - the grand opening of Russia's first plant of GEROPHARM-Bio for the full-cycle production of recombinant human insulin
  • GEROPHARM brought on the market new generic drug Levetinol® for the treatment of various forms of epilepsy

2013-2012:


  • GEROPHARM Company is constantly attending major foreign events in the pharmaceutical market, in particular, the international exhibition BIO International Convention. Every year the company takes part in more than 500 professional events in Russia and abroad
  • According to "TechUspech", the company was included in the rating of fast-developing innovative Russian companies - TOP30 (2012), TOP10 (2013)

2012:


  • GEROPHARM became a resident of the pharmaceutical cluster in the Moscow region
  • In order to implement the unified concept of strategic development, National Biotechnologies was renamed into GEROPHARM-Bio and included into GEROPHARM Group as an enterprise engaged in the development and production of biotechnology drugs
  • The company's sales in Russia reached 2 million packages per year

2012-2011:


  • Representative offices were opened in Kazakhstan, Belarus and Georgia, sales market was expanded in the neighboring countries and South-East Asia

2011:


  • The company had started an active outreach and awareness-raising work on the problem of socially significant diseases in Russia
  • GEROPHARM inaugurated R&D centre in the "Neudorf" SEZ

2010:


  • The company became a member of the Russian Chamber of Commerce
  • An investment agreement was signed at the XIV St.Petersburg International Economic Forum between the Government of St. Petersburg and GEROPHARM on the construction of a pharmaceutical production complex in Pushkin within the pharmaceutical cluster of St. Petersburg
  • Sales volume of drugs crossed the point of 5 million packages

2009:


  • A new finished dosage form of Cortexin® was registered -5 mg Cortexin for children, also promotion of Rinsulin® R (short-acting) and Rinsulin® NPH (intermediate-acting) was started. Total annual revenue reached 1 billion RUB